
What You Should Know:
– Plexāā, a medtech company focused on improving surgical outcomes, has announced the U.S. launch of its BLOOM43 platform on the first day of Breast Cancer Awareness Month.
– The platform combines a wearable preconditioning medical device with a companion app, both developed to prepare patients for breast surgery. The launch addresses a significant need, as surveys show that a majority of patients feel both physically (61%) and mentally (71%) underprepared for breast surgery.
Boosting Tissue Health Before the First Incision
Breast surgery—whether oncological, reconstructive, or cosmetic—carries risks, with wound complications occurring in up to 30% of reconstruction or implant procedures. Skin necrosis (tissue death) due to compromised blood flow remains a critical concern, often requiring additional procedures, delaying healing, and increasing costs.
The BLOOM43 device is the first-ever wearable to deliver Supraphysiological Preconditioning™. This novel, evidence-based technique works by precisely heating the skin at the intended surgical site, which stimulates the release of heat shock proteins and enhances blood flow.
In clinical trials, Supraphysiological Preconditioning has been shown to:
- Decrease the absolute risk of skin necrosis by 24%.
- Reduce the number of required follow-up surgeries by 50%.
- Reduce hospital stays by two days and outpatient follow-ups by 70%.
Empowering Patients with a Holistic Prehab Program
The BLOOM43 device is a non-invasive, drug-free, hands-free wearable that patients use at home, typically the night prior to surgery.
Complementing the device is a thorough and evidenced-based Prehab™ program delivered through the companion app. The app offers guidance on pre-op nutrition and physical health, along with expert content, personalized Prehab and rehab programs, and a supportive community.
According to Dr. Saahil Mehta, CEO and founder of Plexāā, BLOOM43 gives women a way to make critical improvements to tissue health before the first incision, empowering and supporting patients at every step of the journey. A patient and nine-year breast cancer survivor, Nichole W. Owens, shared that using the device before her most recent surgery made her feel “empowered and prepared”.
Availability
The BLOOM43 device is now being prescribed by surgeons and is available for hospitals, surgical centers, and clinics across the U.S.. The companion app is available globally, and U.S. patients can directly order the HSA- and FSA eligible medical device with a prescription.